1,128 assets in Non-Small Cell Lung Carcinoma

Therapeutic assets addressing Non-Small Cell Lung Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Vepdegestrant Non-Small Cell Lung Carcinoma	Pfizer	P2	CCC (51)
Anastrozole Non-Small Cell Lung Carcinoma	Eli Lilly and Company	P2	CCC (50)
Apsolol Non-Small Cell Lung Carcinoma	Second Xiangya Hospital of Central South University	P2	CCC (50)
Bebt-109 Non-Small Cell Lung Carcinoma	BeBetter Med Inc	P2	CCC (50)
Bemcentinib Non-Small Cell Lung Carcinoma	BerGenBio ASA	P2	CCC (50)
Bgb-A445 Non-Small Cell Lung Carcinoma	BeiGene	P2	CCC (50)
Cmp 001 Non-Small Cell Lung Carcinoma	Pfizer	P3	CCC (50)
Cypate-Cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Lys-Oh (Ls301) Non-Small Cell Lung Carcinoma	Integro Theranostics	P2	CCC (50)
Ezabenlimab Non-Small Cell Lung Carcinoma	Institut Bergonié	P2	CCC (50)
Guadecitabine Non-Small Cell Lung Carcinoma	Italian Network for Tumor Biotherapy Foundation	P2	CCC (50)
hlx43 Non-Small Cell Lung Carcinoma	Shanghai Henlius Biotech	P2	CCC (50)
Ifinatamab Deruxtecan Non-Small Cell Lung Carcinoma	Merck Sharp & Dohme LLC	P2	CCC (50)
Infliximab Non-Small Cell Lung Carcinoma	M.D. Anderson Cancer Center	P1/2	CCC (50)
Ipatasertib Non-Small Cell Lung Carcinoma	Jun Zhang, MD, PhD	P2	CCC (50)
Ivuxolimab Non-Small Cell Lung Carcinoma	Pfizer	P3	CCC (50)
JYP0322 Non-Small Cell Lung Carcinoma	Guangzhou JOYO Pharma Co., Ltd	P3	CCC (50)
Lorlatanib Non-Small Cell Lung Carcinoma	Pfizer	P3	CCC (50)
Minocycline Non-Small Cell Lung Carcinoma	Janssen Research & Development, LLC	P2	CCC (50)
rc108 Non-Small Cell Lung Carcinoma	RemeGen Co., Ltd.	P2	CCC (50)
Shr-A1921 Non-Small Cell Lung Carcinoma	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	P2	CCC (50)
(-)-Sirpiglenastat Non-Small Cell Lung Carcinoma	NYU Langone Health	P2	CCC (50)
Sitravatinib Non-Small Cell Lung Carcinoma	Sarah Goldberg	P3	CCC (50)
Umeclidinium Non-Small Cell Lung Carcinoma	Samsung Medical Center	P3	CCC (50)
Vilanterol Non-Small Cell Lung Carcinoma	Samsung Medical Center	P3	CCC (50)
vs-7375 Non-Small Cell Lung Carcinoma	Verastem, Inc.	P2	CCC (50)
alk202 Non-Small Cell Lung Carcinoma	Shanghai Allink Biotherapeutics Co., Ltd.	P2	CCC (49)
Alpelisib Non-Small Cell Lung Carcinoma	Wen-zhao ZHONG	P2	CCC (49)
c105 Non-Small Cell Lung Carcinoma	University of Washington	P2	CCC (49)
cd105/yb-1/sox2/cdh3/mdm2-polyepitope plasmid dna vaccine Non-Small Cell Lung Carcinoma	University of Washington	P2	CCC (49)
Imaradenant Non-Small Cell Lung Carcinoma	MedImmune LLC	P1/2	CCC (49)
Jbi-802 Non-Small Cell Lung Carcinoma	The Christ Hospital	P2	CCC (49)
Maat033 Non-Small Cell Lung Carcinoma	Gustave Roussy, Cancer Campus, Grand Paris	P2	CCC (49)
Quemliclustat Non-Small Cell Lung Carcinoma	Gilead Sciences	P2	CCC (49)
Rmc-4630 Non-Small Cell Lung Carcinoma	The Netherlands Cancer Institute	P2	CCC (49)
Sctb41 Non-Small Cell Lung Carcinoma	Sinocelltech Ltd.	P2	CCC (49)
Spartalizumab Non-Small Cell Lung Carcinoma	Novartis Pharmaceuticals	P2	CCC (49)
Sry-Box Transcription Factor 2 Non-Small Cell Lung Carcinoma	University of Washington	P2	CCC (49)
Surufatinib Non-Small Cell Lung Carcinoma	Sun Yat-sen University	P2	CCC (49)
Tafolecimab Non-Small Cell Lung Carcinoma	Anhui Provincial Cancer Hospital	P2	CCC (49)
Vemurafenib Non-Small Cell Lung Carcinoma	Shanghai Kechow Pharma, Inc.	P2/3	CCC (49)
Vistusertib Non-Small Cell Lung Carcinoma	AstraZeneca	P2	CCC (49)
Whole Agonist-Stimulated T Cells Non-Small Cell Lung Carcinoma	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (49)
Yb-1 Non-Small Cell Lung Carcinoma	University of Washington	P2	CCC (49)
Young Til Non-Small Cell Lung Carcinoma	National Cancer Institute (NCI)	P2	CCC (49)
a2b395 Non-Small Cell Lung Carcinoma	A2 Biotherapeutics Inc.	P1/2	CCC (48)
Ametinib Non-Small Cell Lung Carcinoma	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	P2	CCC (48)
Amt-116 Non-Small Cell Lung Carcinoma	Multitude Therapeutics Inc.	P1/2	CCC (48)
Aurora A Kinase Inhibitor Ly3295668 Non-Small Cell Lung Carcinoma	M.D. Anderson Cancer Center	P1/2	CCC (48)
Bbt-207 Non-Small Cell Lung Carcinoma	Bridge Biotherapeutics, Inc.	P1/2	CCC (48)
Disitamab Vedotin Non-Small Cell Lung Carcinoma	Guangdong Provincial People's Hospital	P2	CCC (48)

Showing 351 to 400 of 1,125 assets

PreviousPage 8 of 23Next